The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Flatiron Health
Muscle invasive bladder cancer (MIBC) demonstrates neoadjuvant cisplatin-based chemotherapy (NAC) related changes in molecular subtype and immune infiltration.
 
Samuel Aaron Funt
Stock and Other Ownership Interests - Allogene Therapeutics; Allogene Therapeutics; Hubble (I); Kite, a Gilead company; Second Science; Urogen pharma (I)
Research Funding - AstraZeneca; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Alexander Solovyov
Consulting or Advisory Role - PMV Pharma
 
Bishoy Morris Faltas
Honoraria - Digital Science Press
Research Funding - Lilly
 
Gopa Iyer
Consulting or Advisory Role - Bayer
 
Mariel Elena Boyd
No Relationships to Disclose
 
Catharine Kline Cipolla
Employment - Triage Consulting Group
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Min Yuen Teo
Research Funding - Bristol-Myers Squibb
 
Chung-Han Lee
Consulting or Advisory Role - Eisai; Eisai; Exelixis; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai
 
Hikmat Al-Ahmadie
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Medscape; Peerview; UpToDate; Vindico
Consulting or Advisory Role - Adicet Bio; Agensys; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; Inovio Pharmaceuticals; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Sanofi; Seagen; Sensei Biotherapeutics
Research Funding - Agensys (Inst); Bayer (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Seagen (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Benjamin Greenbaum
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Merck
Consulting or Advisory Role - DarwinHealth; Merck; PMV Pharma
Patents, Royalties, Other Intellectual Property - WO201613048 A1
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma